0.23
-6.56%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China NT Pharma Group Co
Its shares trade on HKEX under the ticker 1011.HK. It has been listed since 20 April 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥24.2m and a net loss of CN¥26.0m. At that date it held total assets of CN¥347.5m and shareholders' equity of −CN¥273.7m.
China NT Pharma Group Co., Ltd. is a pharmaceutical company, which engages in the distribution, promotion, manufacturing as well as research and development of pharmaceuticals and vaccines. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2011-04-20. The firm mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Apr 2011
- Employees
- 124
- Website
- ntpharma.com ↗
Leadership
Pay as last reported
- Mr. Tit NgExecutive Chairman of the Board, since 2025CN¥1.5m
- Mr. Bozhi ZhangChief Executive Officer
- Ms. Ching Mei NgExecutive Director, since 2024
- Mr. Cheung ChengCompany Secretary
- Ms. Yu ChinNon-Executive Director, since 2010
- Dr. Wei QianNon-Executive Director
- Mr. Ming Kwan NgIndependent Non-Executive Director
- Mr. Tze Shan YuIndependent Non-Executive DirectorCN¥207,000
- Mr. Yubiao ZhaoIndependent Non-Executive DirectorCN¥207,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China NT Pharma Group has 124 employees focused on pharmaceutical R&D and manufacturing.
- Proprietary Product Production and Sales segment drives revenue through NT branded products and generics.
- Miacalcic segment specializes in bone pain treatment with injectable and nasal spray products.
Weaknesses
- The company's IPO date of 20 April 2011 indicates limited market history.
- Suzhou headquarters location may restrict access to global markets.
- The firm's two business segments rely on specific product lines with narrow focus.
Opportunities
- Expanding Miacalcic segment into new markets could increase bone pain treatment sales.
- Growing demand for generic drugs presents opportunities in Proprietary Product segment.
- Suzhou's location in Jiangsu province offers access to regional healthcare networks.
Threats
- Competition from other pharmaceutical companies in the Health Care sector.
- Regulatory changes in China's pharmaceutical industry could impact operations.
- The company's small employee count of 124 may limit scalability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.